GC Biopharma Corp. 006280
KRX · South Korea · Health Technology
KRW 129,300.00+6,300.00 (+5.12%)
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Combines Osivax's proprietary OVX836 T-cell vaccine and technology with GC Biopharma's marketed influenza vaccine and worldwide manufacturing expertisePositions Osivax as the global development lead for a differentiated next-generation influenza vaccine candidateAims to deliver enhanced and more durable protection against highly mutating seasonal influenza strains Lyon, France and Yongin, Republic of Korea – 27 August 2026 - Osivax, a clinical-stage biopharmaceutical company developing different
GC Biopharma (006280.KS), a leading global pharmaceutical company based in South Korea, announced today that its Hunter syndrome treatment, 'Hunterase IV', has received marketing authorization from India's Central Drugs Standard Control Organisation (CDSCO) and Taiwan's Food and Drug Administration (TFDA). Additionally, 'Hunterase ICV' (brand name in Taiwan: Irifaze ICV), an intracerebroventricular infusion, has also been approved by the Taiwan TFDA.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.